BioTuesdays

Category - Developments

Viking Therapeutics Logo
Developments

Viking submits IND for Phase 2 trial of VK2809

Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...

November 17, 2015
Dipexium Pharmaceuticals
Developments

Dipexium Phase 3 Locilex trials 62% enrolled

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled...

November 16, 2015
Avivagen
Developments

Avivagen, COFCO to conduct OxC-beta trial on pigs

Avivagen (TSX-V:VIV) and COFCO Nutrition and Health Research Institute (NHRI), an affiliate of the Chinese government’s COFCO Group, have agreed to conduct a trial of OxC-beta Livestock as a feed additive for swine. The...

November 2, 2015
Avivagen
Developments

Avivagen in credit facility with Bloom Burton

Avivagen (TSX-V:VIV) has signed an agreement with the Bloom Burton Healthcare Lending Trust for a secured drawdown credit facility of up to $1.8-million. The facility will advance Avivagen’s plans for commercializing...

November 2, 2015
Transition Therapeutics
Developments

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...

October 30, 2015
novadaq
Developments

Novadaq Q3 revenue climbs 40%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago. Product sales increased by $5.2-million, or 47%, primarily...

October 28, 2015
Avivagen
Developments

Avivagen sets OxC-beta swine trial in Vietnam

Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine. Earlier this year, Avivagen and NIAS...

October 26, 2015
Titan Pharmaceuticals Logo
Developments

Obama to expand MAT in opioid addiction

President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an order giving...

October 22, 2015